lusutrombopag
Selected indexed studies
- Lusutrombopag. (, 2006) [PMID:34813257]
- Lusutrombopag Is Safe and Efficacious for Treatment of Thrombocytopenia in Patients With and Without Hepatocellular Carcinoma. (Clin Gastroenterol Hepatol, 2020) [PMID:32205226]
- Lusutrombopag: A Review in Thrombocytopenia in Patients with Chronic Liver Disease Prior to a Scheduled Procedure. (Drugs, 2019) [PMID:31529283]
_Worker-drafted node — pending editorial review._
Connections
lusutrombopag is a side effect of
Sources
- Lusutrombopag. (2006) pubmed
- Lusutrombopag Is Safe and Efficacious for Treatment of Thrombocytopenia in Patients With and Without Hepatocellular Carcinoma. (2020) pubmed
- Lusutrombopag: A Review in Thrombocytopenia in Patients with Chronic Liver Disease Prior to a Scheduled Procedure. (2019) pubmed
- Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures: A Systematic Review and Meta-analysis. (2022) pubmed
- Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures. (2023) pubmed
- [Clinical research progress of lusutrombopag for the treatment of thrombocytopenia in chronic liver disease]. (2024) pubmed
- Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis. (2020) pubmed
- Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures. (2019) pubmed
- Lusutrombopag: First Global Approval. (2016) pubmed
- Lusutrombopag as a Repurposing Drug in Combination with Aminoglycosides against Vancomycin-Resistant Enterococcus. (2024) pubmed